Arcellx(ACLX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Arcellx Provides Second Quarter 2024 Financial Results and Business Updates — Earned a $68M milestone payment from Kite for iMMagine-1 enrollment — — Submitted an abstract for the iMMagine-1 study at the 66th ASH Annual Meeting — — The global Phase 3 trial, iMMagine-3, has been initiated by Kite — — U.S. FDA clears anito-cel IND application for myasthenia gravis, an autoimmune disease — REDWOOD CITY, Calif., August 8, 2024 (BUSINESS WIRE) — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company ...